Connect with us

Published

on

Government researchers have found that a widely prescribed asthma drug originally sold by Merck & Co may be linked to serious mental health problems for some patients, according to a scientific presentation reviewed by Reuters.

The US researchers found that the drug, sold under the brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.

Singulair was a blockbuster product for Merck after its launch in 1998, offering relief in a pill as an alternative to an inhaler. In early advertising, the company said the side effects were so benign that they were “similar to a sugar pill,” while the label said any distribution in the brain was “minimal.” Generic versions are still prescribed to millions of adults and children every year.

But by 2019, thousands of reports of neuropsychiatric episodes, including dozens of suicides, in patients prescribed the drug had piled up on internet forums and in the US Food and Drug Administrations tracking system. Such “adverse event” reports do not prove a causal link between a medicine and a side effect, but are used by the FDA to determine whether more study of a drugs risks are warranted.

After years of analysis, the reports and new scientific research led the FDA in 2020 to add a “black box” warning to the montelukast prescribing label, flagging serious mental health risks like suicidal thinking or actions.

The agency also convened a group of internal experts around the same time to look into why the drug might trigger neuropsychiatric side effects.

The results of the group’s work, which are preliminary and have not been previously reported or released publicly, were presented to a limited audience at the American College of Toxicology meeting in Austin, Texas on Wednesday.

The FDA said it does not plan to update the drug label based on data from the presentation.

The behavior of montelukast appears similar to other drugs known to have neuropsychiatric effects, such as the antipsychotic risperidone, according to FDA slides reviewed by Reuters. The FDA has cautioned that its studies are ongoing, and results have not been finalized.

When the FDA added the black box, it cited research from Julia Marschallinger and Ludwig Aigner at Austria’s Institute of Molecular Regenerative Medicine.

The two scientists told Reuters on Thursday the new data showed significant quantities of montelukast present in the brain. The receptors involved play a role in governing mood, impulse control, cognition and sleep, among other functions, they said.

The research does not show whether that binding mechanism leads directly to harmful effects in individual patients, or who is particularly at risk, the two scientists said. However, Marschallinger said the new data bolsters reports from people who reported suffering side effects.

“It’s definitely doing something that’s concerning,” she said.

A Merck representative did not respond to questions. Organon, a Merck spinoff that now markets Singulair, said in a statement it is confident in the drug’s safety profile.

“The product label for Singulair contains appropriate information regarding Singulair benefits, risks and reported adverse reactions,” the company said.

Reuters reported last year that the FDA had received thousands of reports of patients, including many children, experiencing depression, suicidal thoughts and behaviors, or other psychiatric problems after they began using montelukast.

By 2019, the FDA tallied 82 suicides linked to Singulair and its generic versions reported to its adverse-event database since 1998. At least 31 of those reports involved someone 19 or younger.

Subscribe to our weekly Post Care newsletter!

Please provide a valid email address.

By clicking above you agree to the Terms of Use and Privacy Policy.

Never miss a story.

Robert England’s 22-year-old son Nick killed himself in 2017 less than two weeks after starting montelukast. England recalls that his son had trouble sleeping before he died, and said he was completely healthy and had no mental health problems prior to taking the drug.

“He was on that medication for just days, literally just days,” England said. “It completely changed the trajectory of our lives.”

The Reuters report also detailed lawsuits alleging that Merck knew from its early research that the drug could impact the brain and minimized the potential for psychiatric problems in statements to regulators. Many of those lawsuits are still pending.

If you are struggling with suicidal thoughts or are experiencing a mental health crisis and live in New York City, you can call 1-888-NYC-WELL for free and confidential crisis counseling. If you live outside the five boroughs, you can dial the 24/7 National Suicide Prevention hotline at 988 or go to SuicidePreventionLifeline.org.

Continue Reading

Politics

Migrants to be deported to France ‘within weeks’ – as Farage vows to scrap human rights law

Published

on

By

Migrants to be deported to France 'within weeks' - as Farage vows to scrap human rights law

Nigel Farage has said he would scrap the UK’s human rights law to enable the mass deportation of illegal migrants, as the government reportedly prepares to send more than 100 small boat arrivals back to France.

Writing in The Daily Telegraph ahead of a speech later today, the Reform leader said the Human Rights Act would be ripped up should he become prime minister.

Politics Hub: Follow live updates

He would also take the country out of the European Convention on Human Rights (ECHR) and other international treaties, describing them as “malign influences” which had been “allowed to frustrate deportations”.

Pulling Britain out of the ECHR would make it one of only three European countries not signed up – the others being Russia and Belarus.

The UK’s Human Rights Act, Reform say, would be replaced by a British Bill of Rights. This would only apply to British citizens and those with a legal right to live in the UK.

Small boat arrivals would have no right to claim asylum. They would be housed at old military bases before being deported to their country of origin, or third countries like Rwanda.

Please use Chrome browser for a more accessible video player

Will Starmer’s migration tough talk deliver?

One in, one out

Sir Keir Starmer, meanwhile, is said to be ready to implement one of his major policies to tackle the small boats crisis within weeks.

According to The Times, the one in, one out migrant deal he signed with France’s Emmanuel Macron earlier this summer will soon see more than 100 people sent back.

The newspaper reported there are dozens of migrants currently in detention, including some arrested over the bank holiday weekend, who could be among the first sent back to France.

In exchange, the UK would be expected to take an equal number of asylum seekers in France with ties to Britain.

Read more: How will the one in, one out deal work?

Sir Keir Starmer hopes his deal with Emmanuel Macron will help. Pic: Reuters
Image:
Sir Keir Starmer hopes his deal with Emmanuel Macron will help. Pic: Reuters

A record 28,288 people have crossed the Channel in small boats this year. The total is 46% higher than at the same stage last year.

More boats were seen crossing on Monday, though the figures won’t be published by the Home Office until later.

Sir Keir is under mounting pressure within his own party to grip the issue, with Sir Tony Blair’s former home secretary Lord Blunkett warning the public “will turn on” him.

But they may already have – a YouGov poll over the weekend found 71% of people think the prime minister is dealing with the small boats crisis badly.

Protests have taken place outside hotels used to house asylum seekers over the weekend, and the government is braced for more legal challenges from councils over their use.

Labour have taken a battering in the opinion polls throughout 2025, with Reform consistently in the lead.

Continue Reading

Business

Trump seeks to fire Fed governor, triggering fresh independence crisis

Published

on

By

Trump seeks to fire Fed governor, triggering fresh independence crisis

President Trump says he is firing a governor of the US central bank, a move seen as intensifying his bid for control over the setting of interest rates.

He posted a letter on his Truth Social platform on Monday night declaring that Lisa Cook – the first black woman to be appointed a Federal Reserve governor – was to be removed from her post on alleged mortgage fraud grounds.

She has responded, insisting he has no authority over her job and vowed to continue in the role, threatening a legal battle that could potentially go all the way to the Supreme Court.

Money latest: ‘RAC left me stranded on a busy motorway for four hours – then gave me £8’

The president‘s threat is significant as he has consistently demanded that the central bank cut interest rates to help boost the US economy. Growth has sagged since he returned to office on the back of US trade war gloom and hiring has slowed sharply in more recent months.

Mr Trump has previously directed his ire over rates at Jay Powell, the chair of the Federal Reserve, blaming him for the economic jitters and has repeatedly called for him to be fired.

The Fed, as it is known, has long been considered an institution independent from politics and question marks over that independence has previously shaken financial markets.

More from Money

The dollar was hit overnight while US futures indicate a negative opening for stock markets.

Mr Powell’s term is due to end next spring and the president is expected to soon nominate his replacement.

Fed chair Jay Powell is seen in discussion with board member Lisa Cook. Pic: AP
Image:
Fed chair Jay Powell is seen in discussion with board member Lisa Cook. Pic: AP

The Fed has 12 people with a right to vote on monetary policy, which includes the setting of interest rates and some regulatory powers.

Those 12 include the seven members of the Board of Governors, of which Ms Cook is one.

Replacing her would give Trump appointees a 4-3 majority on the board.

Please use Chrome browser for a more accessible video player

July: Fed chair has ‘done a bad job’, says Trump

He has previously said he would only appoint Fed officials who support lower borrowing costs.

Ms Cook was appointed to the Fed’s board by then-president Joe Biden in 2022 and is the first black woman to serve as a governor.

Her nomination was opposed by most Senate Republicans at the time and was only approved, on a 50-50 vote, with the tie broken by then-vice president Kamala Harris.

It was alleged last week by a Trump appointed regulator that Ms Cook had claimed two primary residences in 2021 to get better mortgage terms.

Mortgage rates are often higher on second homes or those purchased to rent.

She responded to the president’s letter: “President Trump purported to fire me ‘for cause’ when no cause exists under the law, and he has no authority to do so,” she said in an emailed statement.

“I will not resign.”

Legal experts said it was for the White House to argue its case.

But Lev Menand, a law professor at Columbia law school, said of the situation: “This is a procedurally invalid removal under the statute.

“This is not someone convicted of a crime. This is not someone who is not carrying out their duties.”

The Fed was yet to comment.

It has held off from interest rate cuts this year, largely over fears that the president’s trade war will result in a surge of inflation due to higher import duties being passed on in the world’s largest economy.

However, Mr Powell hinted last week that a cut could now be justified due to risks of rising unemployment.

Continue Reading

Politics

ETF issuers must be picky as most crypto is ‘pretty sketchy,’ REX CEO says

Published

on

By

ETF issuers must be picky as most crypto is ‘pretty sketchy,’ REX CEO says

ETF issuers must be picky as most crypto is ‘pretty sketchy,’ REX CEO says

REX Financial CEO Greg King said the crypto market gets dicey “below the top 10” and ETF issuers should carefully choose what tokens to turn into funds.

Continue Reading

Trending